DiaSorin Stock - Deutsche Bank downgrade adds pressure
17.06.2026 - 17:18:41 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:15 CET. Details in the imprint.
DiaSorin (IT0003497168) is back in analysts' crosshairs after a fresh downgrade from Deutsche Bank. The broker cut its recommendation to Sell and lowered its price target, citing execution risks around the diagnostics group's medium-term growth plans, according to a Firstonline market summary.
All news and analysis on DiaSorin stock
Key analyst opinions, recent trading and corporate updates help investors gauge how DiaSorin is progressing against its post-pandemic diagnostics strategy.
Deutsche Bank turns more cautious
Deutsche Bank downgraded DiaSorin to Sell from Hold and cut its price target to EUR 58 from EUR 62, arguing that consensus expectations for 2026 and 2030 look demanding for the Italian diagnostics group. The move was reported midweek by Firstonline and Investing.com, which highlighted the bank's more skeptical stance.
The German broker points to downside risk versus peers as growth normalizes after the pandemic and as the company works to offset declining COVID-related revenues with its core immunodiagnostic and molecular testing portfolio. According to Investing.com, the new target implies roughly 15% downside versus a recent closing price around EUR 67.30.
How the market is trading the downgrade
The downgrade lands as Milan's FTSE Mib has seen pockets of volatility, with DiaSorin shares recently cited among early decliners, trading about 1.3% lower at EUR 65.56 in one midweek session. Another session left the stock about 1.1% softer while the broader Italian blue chip index advanced, underlining a bout of underperformance for the diagnostics name.
On Wednesday, exchange data showed DiaSorin shares changing hands in a narrow intraday range around the high EUR 60s, with the day's low near EUR 68.50 and high around EUR 69.16 on Borsa Italiana. This trading pattern suggests investors are digesting the downgrade rather than reacting with abrupt repositioning.
Analyst views and earnings trajectory
The Deutsche Bank call adds a more bearish voice to a coverage universe that had largely sat in Neutral territory following DiaSorin's first-quarter update and medium-term guidance reiteration. The bank argues that management's 2026 targets and 2030 growth ambitions may prove optimistic if hospital budgets tighten and routine testing volumes grow only modestly.
DiaSorin itself has indicated that it expects organic sales to move from a 3% decline in the first quarter to a slight increase over the full year as COVID revenues fade and non-COVID diagnostics regain momentum. The market will watch upcoming results closely to see whether this inflection materializes and whether operating margins hold up as mix shifts toward routine testing.
Wednesday focus on operations and strategy
From an operational perspective, DiaSorin continues to emphasize its transition away from COVID-centric demand toward broader specialty testing and molecular platforms. Management has previously highlighted growth opportunities in infectious disease panels, transplant diagnostics and other high-value niches that can support pricing power and recurring reagent revenue.
The group is also investing in automation and instrument placements to deepen its installed base in hospital and reference laboratories, which is key to driving reagent pull-through over the coming years. Successful execution on this strategy is central to bridging the gap between Deutsche Bank's more cautious assumptions and the company's stated long-term revenue and margin ambitions.
The product behind the stock
DiaSorin generates most of its revenue from in vitro diagnostic systems and test kits, notably its LIAISON-branded immunodiagnostic analyzers and related reagents used in hospitals and clinical labs. These tests cover infectious disease, bone and mineral metabolism, hepatitis, cardiac markers and oncology, among other specialty areas.
Where the stock trades today
DiaSorin shares (IT0003497168) trade on Borsa Italiana at about EUR 68.80 as of 06/17/2026, 17:15 CET.
Key facts on DiaSorin stock
- Company: DiaSorin S.p.A.
- ISIN: IT0003497168
- WKN: 925874
- Ticker: DIA
- Venue: Borsa Italiana (Milan)
- Price (as of 06/17/2026, 17:15 CET): 68.80 EUR
- Market cap: 3.90 billion EUR (as of 06/17/2026)
- Sector / Industry: Health Care - In Vitro Diagnostics / Medical Technology
- Index membership: FTSE Mib
- Next earnings date: 08/02/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
